Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Arcturus Therapeutics (ARCT) Tops Q1 EPS by $1.81
May 9, 2023 4:04 PM EDTArcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of $1.87, $1.81 better than the analyst estimate of $0.06. Revenue for the quarter came in at $80.3 million versus the consensus estimate of $37.94 million.
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
... More